Evidence map›Paper›PMID 41774454›Full record

ReviewThe Biochemical journal2026

Structural and mechanistic basis of mTORC2 activation of protein kinase AKT/PKB.

Nam Chu, Nhat Le, Ouada Nebie, Sammi Yang

Abstract readReview
In one paragraph

Review in The Biochemical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nam ChuDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH 43210, U.S.A.ORCID 0000-0001-9717-5007
Nhat LeDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH 43210, U.S.A.ORCID 0000-0003-0528-8114
Ouada NebieDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH 43210, U.S.A.ORCID 0000-0002-6802-4215
Sammi YangDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH 43210, U.S.A.

Funding

Chemoenzymatic Protein Semisynthesis Approaches Toward Cell Signaling EnzymesR35GM151124 · NIGMS · OHIO STATE UNIVERSITY · PI Nam Ky Chu · 2023 to 2026
$1.6M
Mechanisms Of Akt RegulationK22CA241105 · NCI · OHIO STATE UNIVERSITY · PI CHU, NAM KY · 2021 to 2023
$562k
NCI NIH HHS K22CA241105NIGMS NIH HHS R35 GM151124NIGMS NIH HHS R35GM151124
6 · The paper itself

Abstract

The PI3K/AKT/mTOR signaling pathway is crucial for regulating essential cellular processes such as growth, survival, metabolism, and protein synthesis. Dysregulation of this pathway is strongly associated with diseases like cancer, where it drives uncontrolled cell proliferation and survival. The mTOR kinase forms two multiprotein complexes, mTORC1 and mTORC2, which govern distinct signaling pathways. mTORC1, regulated by nutrients, controls protein synthesis, cell growth, and autophagy, while mTORC2 acts as a central node in phosphoinositide 3-kinase (PI3K) and Ras signaling, often disrupted in cancer and diabetes. AKT, recruited by PIP3 to the plasma membrane, is phosphorylated by PDK1 and mTORC2, enabling it to regulate various cellular functions. Notably, mTORC2 selectively phosphorylates AKT and PKC but no other closely related kinases targeted by mTORC1, reflecting a high degree of substrate specificity. This specificity is due to structural elements in AKT that interact with the mTORC2 subunit mSin1 as revealed by recent studies using semisynthetic probes, paving the way for the design of mTORC2-specific inhibitors. Given the pathway's significant role in disease progression, particularly cancer, targeting the AKT/mTOR axis holds considerable therapeutic promise. However, challenges remain due to the complex regulation and feedback mechanisms in this pathway. Emerging combination therapies show promise in overcoming these obstacles. This review highlights the intricate regulation of the AKT/mTOR pathway and its potential for developing targeted therapies.

Indexed as

Mechanistic Target of Rapamycin Complex 2Proto-Oncogene Proteins c-aktAnimalsEnzyme ActivationHumansPhosphorylationSignal TransductionMechanistic Target of Rapamycin Complex 2Proto-Oncogene Proteins c-aktAKTcell signalingmTORposttranslational modificationsprotein kinase

Identifiers

PMID41774454
PMCPMC13089146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.